List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6739045/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	13.5	1,742
2	A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. Cell, 2004, 119, 591-602.	13.5	1,158
3	Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. International Journal of Cancer, 2010, 126, 73-80.	2.3	401
4	MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Research, 2006, 66, 5104-5110.	0.4	277
5	Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell, 2002, 2, 9-15.	7.7	182
6	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunology Research, 2019, 7, 923-938.	1.6	148
7	Frequent hypermethylation ofMST1 andMST2 in soft tissue sarcoma. Molecular Carcinogenesis, 2007, 46, 865-871.	1.3	144
8	Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Therapy, 2004, 11, 186-193.	2.2	103
9	Significance ofHDMX-S (orMDM4) mRNA splice variant overexpression andHDMX gene amplification on primary soft tissue sarcoma prognosis. International Journal of Cancer, 2005, 117, 469-475.	2.3	88
10	Increased survivin transcript levels: An independent negative predictor of survival in soft tissue sarcoma patients. International Journal of Cancer, 2001, 95, 360-363.	2.3	86
11	Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet, The, 2002, 359, 943-945.	6.3	83
12	Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. International Journal of Cancer, 2001, 92, 577-582.	2.3	80
13	High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene, 1998, 16, 1183-1185.	2.6	77
14	Amplification of themdm2 gene, but not expression of splice variants ofmdm2 mrna, is associated with prognosis in soft tissue sarcoma. International Journal of Cancer, 2001, 95, 168-175.	2.3	76
15	Comparative microRNA Profiling of Prostate Carcinomas with Increasing Tumor Stage by Deep Sequencing. Molecular Cancer Research, 2014, 12, 250-263.	1.5	75
16	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European Journal of Cancer, 2019, 106, 234-243.	1.3	75
17	Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer, 2013, 13, 71.	1.1	74
18	Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Renal Cell Carcinoma Correlates with Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2190-2194.	1.1	72

#	Article	IF	CITATIONS
19	Identification of ZNF217, hnRNPâ€K, VECFâ€A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. International Journal of Cancer, 2013, 132, 775-784.	2.3	70
20	Coexpression of hypoxia-inducible factor-1α and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology, 2011, 58, 1136-1147.	1.6	66
21	Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer. Cancer Research, 2012, 72, 4074-4084.	0.4	58
22	Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. OncoImmunology, 2015, 4, e1008805.	2.1	58
23	Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clinical Cancer Research, 2003, 9, 1098-104.	3.2	58
24	Prognostic Impact of HIF-1α Expression in Patients with Definitive Radiotherapy for Cervical Cancer. Strahlentherapie Und Onkologie, 2008, 184, 169-174.	1.0	56
25	The protoâ€oncogene <scp>ERG</scp> is a target of micro <scp>RNA </scp> <i>miRâ€145</i> in prostate cancer. FEBS Journal, 2013, 280, 2105-2116.	2.2	56
26	Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-11±-related markers, and hemoglobin levels. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1481-1487.	0.4	55
27	Alterations of cancer-related genes in soft tissue sarcomas: Hypermethylation ofRASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. International Journal of Cancer, 2005, 114, 442-447.	2.3	50
28	Gains of 13q are correlated with a poor prognosis in liposarcoma. Modern Pathology, 2005, 18, 638-644.	2.9	49
29	Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Identification of seven new mutations for soft tissue sarcomas. Cancer, 1995, 76, 1187-1196.	2.0	47
30	<i>MDM2</i> and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides. Molecular Cancer Research, 2004, 2, 29-35.	1.5	47
31	A Three-Gene Signature for Outcome in Soft Tissue Sarcoma. Clinical Cancer Research, 2009, 15, 5191-5198.	3.2	45
32	Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3Ï,, and CD44 That Affect Sarcoma Incidence and Survival. Cancer Research, 2010, 70, 172-180.	0.4	45
33	The combined serum levels of <i>miR-375</i> and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. International Journal of Cancer, 2015, 137, 1406-1416.	2.3	45
34	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. , 2020, 8, e000162.		45
35	Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients. Oncotarget, 2018, 9, 10402-10416.	0.8	44
36	A RASSF1A Polymorphism Restricts p53/p73 Activation and Associates with Poor Survival and Accelerated Age of Onset of Soft Tissue Sarcoma. Cancer Research, 2012, 72, 2206-2217.	0.4	42

#	Article	IF	CITATIONS
37	Frequent occurrence ofp53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. , 1996, 69, 317-323.		38
38	Immunohistochemical Detection of HIF-1α and CAIX in Advanced Head-and-Neck Cancer. Strahlentherapie Und Onkologie, 2008, 184, 393-399.	1.0	38
39	HIF-1α is a Prognostic Marker in Oral Squamous Cell Carcinomas. International Journal of Biological Markers, 2010, 25, 87-92.	0.7	38
40	HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget, 2016, 7, 67360-67372.	0.8	38
41	Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. Radiation Oncology, 2011, 6, 111.	1.2	37
42	Cytogenetic characterization of six malignant peripheral nerve sheath tumors. Cancer Genetics and Cytogenetics, 2001, 128, 14-23.	1.0	36
43	Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene, 2005, 24, 5258-5261.	2.6	36
44	Effects of osteopontin inhibition on radiosensitivityof MDA-MB-231 breast cancer cells. Radiation Oncology, 2010, 5, 82.	1.2	36
45	Salivary miR-93 and miR-200a as post-radiotherapy biomarkers in head and neck squamous cell carcinoma. Oncology Reports, 2017, 38, 1268-1275.	1.2	36
46	Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. Journal of Cancer Research and Clinical Oncology, 1997, 123, 502-508.	1.2	34
47	Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. Gynecologic Oncology, 2004, 92, 256-261.	0.6	34
48	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	0.8	33
49	Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncology Reports, 2005, 13, 167-72.	1.2	33
50	Soft Tissue Sarcomas and p53 Mutations. Molecular Medicine, 1998, 4, 365-372.	1.9	32
51	Nuclear E-cadherin Expression is Associated with the Loss of Membranous E-cadherin, Plasmacytoid Differentiation and Reduced Overall Survival in Urothelial Carcinoma of the Bladder. Annals of Surgical Oncology, 2013, 20, 2440-2445.	0.7	32
52	The real face of HIF1 \hat{I} ± in the tumor process. Cell Cycle, 2012, 11, 3932-3936.	1.3	31
53	Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer, 2010, 10, 132.	1.1	30
54	Betulinic Acid Derivatives NVX-207 and B10 for Treatment of Glioblastoma—An in Vitro Study of Cytotoxicity and Radiosensitization. International Journal of Molecular Sciences, 2014, 15, 19777-19790.	1.8	30

#	Article	IF	CITATIONS
55	Piwi-like 1 and 4 gene transcript levels are associated with clinicopathological parameters in renal cell carcinomas. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 686-690.	1.8	30
56	mdm2 mRNA Level is a Prognostic Factor in Soft Tissue Sarcoma. Molecular Medicine, 2000, 6, 50-59.	1.9	29
57	Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. Journal of Clinical Medicine, 2019, 8, 743.	1.0	29
58	Elevated Transcript Levels From the MDM2 P1 Promoter and Low p53 Transcript Levels Are Associated With Poor Prognosis in Human Pancreatic Ductal Adenocarcinoma. Pancreas, 2011, 40, 265-270.	0.5	28
59	Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer, 2010, 10, 65.	1.1	27
60	Normoxic accumulation of HIF1α is associated with glutaminolysis. Clinical Oral Investigations, 2017, 21, 211-224.	1.4	27
61	Prognostic Relevance of C-terminal Mdm2 Detection Is Enhanced by p53 Positivity in Soft Tissue Sarcomas. Diagnostic Molecular Pathology, 1997, 6, 249-254.	2.1	26
62	Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM Remodeling. Cancer Research, 2021, 81, 1552-1566.	0.4	26
63	Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. Gynecologic Oncology, 2007, 104, 139-144.	0.6	24
64	Recent Natural Selection Identifies a Genetic Variant in a Regulatory Subunit of Protein Phosphatase 2A that Associates with Altered Cancer Risk and Survival. Clinical Cancer Research, 2009, 15, 6301-6308.	3.2	23
65	MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation. Pancreas, 2010, 39, 76-80.	0.5	23
66	High coexpression of <i>CCL2</i> and <i>CX3CL1</i> is genderâ€specifically associated with good prognosis in soft tissue sarcoma patients. International Journal of Cancer, 2014, 135, 2096-2106.	2.3	23
67	Elevated HERV-K Expression in Soft Tissue Sarcoma Is Associated with Worsened Relapse-Free Survival. Frontiers in Microbiology, 2018, 9, 211.	1.5	23
68	Targeting of EGFR and HER2 with therapeutic antibodies and siRNA. Strahlentherapie Und Onkologie, 2015, 191, 180-191.	1.0	22
69	Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World Journal of Urology, 2021, 39, 4011-4019.	1.2	22
70	Expression of human Piwi-likegenes is associated with prognosis for soft tissue sarcoma patients. BMC Cancer, 2012, 12, 272.	1.1	21
71	Piwil 2 Expression Is Correlated with Disease-Specific and Progression-Free Survival of Chemotherapy-Treated Bladder Cancer Patients. Molecular Medicine, 2015, 21, 371-380.	1.9	21
72	P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients. Clinical and Translational Radiation Oncology, 2017, 5, 6-11.	0.9	21

#	Article	IF	CITATIONS
73	CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage. Cancers, 2020, 12, 1253.	1.7	21
74	HIF-1alpha is a prognostic marker in oral squamous cell carcinomas. International Journal of Biological Markers, 2010, 25, 87-92.	0.7	21
75	A novel splice variant of the stem cell marker LGR5/GPR49 is correlated with the risk of tumor-related death in soft-tissue sarcoma patients. BMC Cancer, 2011, 11, 429.	1.1	20
76	Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2019, 20, 375.	1.8	20
77	Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer, 2012, 12, 131.	1.1	19
78	Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism. International Journal of Molecular Sciences, 2019, 20, 4742.	1.8	19
79	RNA Sequencing of Collecting Duct Renal Cell Carcinoma Suggests an Interaction between miRNA and Target Genes and a Predominance of Deregulated Solute Carrier Genes. Cancers, 2020, 12, 64.	1.7	18
80	A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines. Oncotarget, 2017, 8, 11676-11691.	0.8	18
81	Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients. Scientific Reports, 2018, 8, 17693.	1.6	17
82	Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells InÂVitro and InÂVivo. Molecular Therapy - Nucleic Acids, 2019, 16, 272-283.	2.3	17
83	Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. Cancers, 2020, 12, 2794.	1.7	17
84	Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma. Journal of Nanobiotechnology, 2020, 18, 173.	4.2	17
85	Cytogenetic Characterization of Ten Malignant Fibrous Histiocytomas. Cancer Genetics and Cytogenetics, 1998, 100, 134-142.	1.0	16
86	Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer. BioMed Research International, 2014, 2014, 1-9.	0.9	16
87	miR-199a-5p regulates HIF-1α and OSGIN2 and its expression is correlated to soft-tissue sarcoma patients' outcome. Oncology Letters, 2016, 12, 5281-5288.	0.8	16
88	MiRNA-21 Expression Decreases from Primary Tumors to Liver Metastases in Colorectal Carcinoma. PLoS ONE, 2016, 11, e0148580.	1.1	15
89	Immunohistochemical and clinical evaluation of cathepsin expression in soft tissue sarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 430, 221-225.	1.4	14
90	No p16INK4A/CDKN2/MTS1 mutations independent of p53 status in soft tissue sarcomas. , 1998, 184, 14-17.		14

#	Article	IF	CITATIONS
91	Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene. Cancer Letters, 2000, 149, 181-188.	3.2	14
92	CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients. International Journal of Molecular Sciences, 2017, 18, 2648.	1.8	14
93	Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis. BMC Cancer, 2014, 14, 974.	1.1	13
94	Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival. Cancer Management and Research, 2018, Volume 10, 4173-4180.	0.9	13
95	Cytotoxicity of AMANTADIG – a semisynthetic digitoxigenin derivative – alone and in combination with docetaxel in human hormone-refractory prostate cancer cells and its effect on Na+/K+-ATPase inhibition. Biomedicine and Pharmacotherapy, 2018, 107, 464-474.	2.5	13
96	Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays. Laboratory Investigation, 2019, 99, 1527-1534.	1.7	13
97	Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 256-263.	1.4	12
98	Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. International Journal of Oncology, 2002, 21, 521.	1.4	12
99	Genetic control of cell proliferation in female germ line cells of Drosophila: Mosaic analysis of five discless mutations. Molecular Genetics and Genomics, 1987, 209, 545-551.	2.4	11
100	Loss of Heterozygosity at 12q14-15 Often Occurs in Stage I Soft Tissue Sarcomas and Is Associated with MDM2 Amplification in Tumors at Various Stages. Modern Pathology, 2003, 16, 1109-1116.	2.9	11
101	Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients. BMC Cancer, 2011, 11, 273.	1.1	11
102	SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer. Annals of Surgical Oncology, 2013, 20, 3669-3674.	0.7	11
103	Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma. Scientific Reports, 2017, 7, 16424.	1.6	11
104	Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients. Scientific Reports, 2019, 9, 1741.	1.6	11
105	Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. Oncology Reports, 2005, 14, 895.	1.2	10
106	TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers. Genes, 2021, 12, 230.	1.0	10
107	The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. Cancer Management and Research, 2021, Volume 13, 6567-6578.	0.9	10
108	Association of HDM2 Transcript Levels with Age of Onset and Prognosis in Soft Tissue Sarcomas. Molecular Cancer Research, 2008, 6, 1575-1581.	1.5	9

#	Article	IF	CITATIONS
109	Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients. Cancers, 2019, 11, 2029.	1.7	9
110	MiR-155-5p and MiR-203a-3p Are Prognostic Factors in Soft Tissue Sarcoma. Cancers, 2020, 12, 2254.	1.7	9
111	p53 status in radiation-induced soft-tissue sarcomas. Strahlentherapie Und Onkologie, 1998, 174, 427-430.	1.0	8
112	Lack of evidence for frequent <i><scp>MED12</scp></i> p. <scp>L1224F</scp> mutation in prostate tumours from Caucasian patients. Journal of Pathology, 2013, 230, 453-456.	2.1	8
113	Low HIF-11 [±] and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently. International Journal of Molecular Sciences, 2018, 19, 3842.	1.8	8
114	Molecular Composition of Genomic <i>TMPRSS2-ERG</i> Rearrangements in Prostate Cancer. Disease Markers, 2019, 2019, 1-8.	0.6	8
115	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. Cancers, 2021, 13, 2327.	1.7	8
116	Impact of expression of the uPA system in sarcomas. Biomarkers in Medicine, 2013, 7, 473-480.	0.6	7
117	Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. Strahlentherapie Und Onkologie, 2014, 190, 912-918.	1.0	7
118	Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients. BMC Cancer, 2019, 19, 155.	1.1	7
119	Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. Journal of Cancer Research and Clinical Oncology, 1997, 123, 502-508.	1.2	7
120	Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1234-1239.	0.8	6
121	Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy. Cells, 2021, 10, 159.	1.8	6
122	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. Urology, 2021, 157, 93-101.	0.5	6
123	Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 63.e19-63.e26.	0.8	6
124	High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels: molecular predictors for survival of stage 2 soft tissue sarcoma patients. Anticancer Research, 2002, 22, 1553-9.	0.5	6
125	Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls. Cancer Immunology, Immunotherapy, 2017, 66, 565-571.	2.0	5
126	Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients. Cancers, 2020, 12, 2639.	1.7	5

#	Article	IF	CITATIONS
127	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. Carcinogenesis, 2021, 42, 1475-1484.	1.3	5
128	The New Semisynthetic Cardenolide Analog 3β-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines. Anticancer Research, 2015, 35, 5271-5.	0.5	5
129	PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. Cancers, 2020, 12, 2742.	1.7	4
130	GP88/PGRN Serum Levels Are Associated with Prognosis for Oral Squamous Cell Carcinoma Patients. Biology, 2021, 10, 400.	1.3	4
131	Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions. Cells, 2021, 10, 1315.	1.8	4
132	Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients. Cells, 2021, 10, 3223.	1.8	4
133	A Mboll polymorphism in exon 11 of the human MDM2 gene occuring in normal blood donors and in soft tissue sarcoma patients: an indication for an increased cancer susceptibility?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000, 456, 39-44.	0.4	3
134	Optimising the therapeutic ratio in head and neck cancer. Lancet Oncology, The, 2010, 11, 511-512.	5.1	3
135	Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes. Prostate Cancer, 2017, 2017, 1-12.	0.4	3
136	High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. Life, 2021, 11, 642.	1.1	3
137	Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients. Cells, 2021, 10, 1796.	1.8	3
138	Low detection rate of p53 antibodies in sera of soft tissue sarcoma patients. Cancer Letters, 2001, 170, 199-205.	3.2	2
139	Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. International Journal of Cancer, 1996, 69, 317-323.	2.3	1
140	Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients. Life, 2022, 12, 732.	1.1	1
141	Growth reduction of a xenotransplanted human Soft Tissue Sarcoma by MDM2 Antisense Therapy. , 0, 2002, .		0
142	Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors. Life, 2022, 12, 641.	1.1	0